Notable Wednesday Option Activity: DRI, PRAX, TGTX

Praxis Precision Medicines Inc (PRAX) and TG Therapeutics Inc (TGTX) both experienced notably high options trading volume, with PRAX seeing 1,123 contracts (42.8% of average daily share volume) and TGTX 7,099 contracts (42.7% of average daily share volume). Particularly significant activity was observed in PRAX's $35 strike put options expiring July 18, 2025, and TGTX's $33 strike put options expiring August 15, 2025, suggesting concentrated bearish sentiment or hedging strategies around these specific price points and future dates.

Analysis

Praxis Precision Medicines (PRAX) and TG Therapeutics (TGTX) both exhibited significant options market activity, with volumes representing 42.8% and 42.7% of their respective average daily share volumes. This heightened activity was not diffuse but rather concentrated in specific, long-dated put options. For PRAX, notable volume was seen in the $35 strike puts expiring in July 2025, while TGTX saw a surge in its $33 strike puts for August 2025. Such targeted buying in puts with more than a year until expiration indicates strategic positioning rather than short-term tactical trading. This activity could represent either outright bearish speculation on the long-term prospects of these biotechnology firms or, more likely, significant hedging by institutional holders seeking to protect long-stock positions against potential downside from future clinical trial data or regulatory decisions expected before mid-2025.

Key Decisions for Investors

• Investors holding PRAX or TGTX should view this substantial put buying as a potential leading indicator of perceived downside risk and may consider reviewing their own portfolio protection strategies.
• Monitor the open interest for the PRAX July 2025 $35 puts and the TGTX August 2025 $33 puts to confirm if this volume establishes new, large positions, which would reinforce the signal.
• Investigate the clinical and regulatory timelines for both companies to identify potential binary events scheduled before the options' expiration in mid-2025, as these catalysts are likely driving this specific hedging or speculative activity.